Log In
Print this Print this

Cetuximab-based bispecific zybody

  Manage Alerts
Collapse Summary General Information
Company Zyngenia Inc.
DescriptionZybody targeting EGFR and erb-b2 receptor tyrosine kinase 3 (ERBB3; HER3; EGFR3)
Molecular Target Epidermal growth factor receptor (EGFR) ; Erb-b2 receptor tyrosine kinase 3 (ERBB3) (HER3) (EGFR3)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today